Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Ganetespib With Platinum, in Patients With Malignant Pleural Mesothelioma (MESO-02)

This study is ongoing, but not recruiting participants.
Cancer Research UK
Information provided by (Responsible Party):
University College, London Identifier:
First received: April 30, 2012
Last updated: October 26, 2016
Last verified: December 2015

Malignant pleural mesothelioma (MPM) is a rapidly lethal cancer arising from the parietal pleural mesothelium, and is associated with exposure to asbestos.

Once a rare disease, it is increasing in incidence in the UK and is presently more common than cervical cancer. MPM is characterized by local invasion of adjacent structures including the chest wall, mediastinum, diaphragm and pericardium resulting in progressive shortness of breath.

Median survival with best supportive care alone is approximately 6-9 months and most cases of mesothelioma present in the advanced setting. Therefore this trial will be looking at whether a new drug, Ganetespib has any improvement on survival for these types of patients.

Condition Intervention Phase
Lung Cancer - Malignant Pleural Mesothelioma
Drug: Ganetespib
Phase 1
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase I/II Study of First Line Ganetespib With Platinum, in Patients With Malignant Pleural Mesothelioma

Resource links provided by NLM:

Further study details as provided by University College, London:

Primary Outcome Measures:
  • Maximum Tolerated Dose of Ganetespib [ Time Frame: 6 Months ]

    Primary endpoint (phase I): Dose-limiting toxicities during Cycles 1 & 2; and number of cycles of pemetrexed-cisplatin given.

    The Phase I trial will consist of three ganetespib dose cohorts, each with 3 or 6 patients:

    • Cohort 1: 100mg/m2 IV on day 1 and day 15 of each cycle
    • Cohort 2: 150mg/m2 IV on day 1 and day 15 of each cycle
    • Cohort 3: 200mg/m2 IV on day 1 and day 15 of each cycle

    There will be additional patients to be treated with carboplatin (AUC5) instead of cisplatin. If treatment with carboplatin is confirmed to be safe and tolerable, the option of treating patients with either cisplatin or carboplatin during phase II will be taken. The evaluation will be done using an accelerated titrated phase I design.

    Primary endpoint (phase II): Progression free survival

Secondary Outcome Measures:
  • Progression Free Survival [ Time Frame: 24 Months ]

    Secondary endpoints (phase I):

    • To examine the number of cycles of pemetrexed/platinum chemotherapy administered.
    • To examine the objective tumour response according to meso-modified RECIST, and the overall response rate.

    Secondary endpoints (phase II):

    • To examine the frequency of all Adverse Events graded by NCI-CTCAE version 4, in particular those with grade 3 or 4 events.
    • To examine the objective tumour response according to meso-modified RECIST, and the overall response rate.
    • To examine overall survival.

Enrollment: 27
Study Start Date: August 2013
Estimated Primary Completion Date: September 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Cisplatin/Pemetrexed
Cisplatin 75mg/m2, Day 1 every 21 days Pemetrexed 500mg/m2, Day 1 every 21 days
Drug: Ganetespib
IV, Using dose from Phase I
Experimental: Carboplatin/Pemetrexed
Carboplatin AUC5, Day 1 every 21 days Pemetrexed 500mg/m2, Day 1 every 21 days
Drug: Ganetespib
IV, Using dose from Phase I


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Histopathological confirmation of malignant pleural mesothelioma
  2. Measurable disease using meso-modified RECIST criteria (CT scan must be within 28 days of registration/randomisation)
  3. Performance status ECOG 0-1
  4. Age at least 18 years
  5. Adequate haematological status:

    • Haemoglobin 100g/L or greater
    • Neutrophil count ≥2.0 x 10^9/L
    • Platelets ≥100 x 10^9 /L
  6. Adequate organ function:

    • Bilirubin ≤1.5x ULN, ALP ≤2.5x ULN, ALT or AST ≤1.5x ULN
    • Serum creatinine ≤1.5 x ULN or calculated creatinine clearance ≥ 60ml/min (C&G or EDTA)
  7. Chemotherapy naïve
  8. Negative serum pregnancy test for female patients of child bearing potential.
  9. Male subjects and women of child bearing potential must agree to use an acceptable method of birth control for the duration of the trial and for 6 months after the last trial treatment cycle has finished.
  10. Ability to understand and willing to sign the written informed consent to participate (including donation of diagnostic biopsy tissue for research)
  11. Ability to comply with the requirements of the protocol

Exclusion Criteria:

  1. Prior exposure to other investigational or commercial agents or therapies administered with the intent of treating the patient's malignancy. This includes crizotinib, other ALK-targeted agents, and any Hsp90 inhibitor (e.g. ganetespib). Prior valproic acid is acceptable but only if there has been at least 30 days wash-out period
  2. Evidence of CNS metastases that in the opinion of the investigator should receive local treatment prior to systemic cytotoxic chemotherapy
  3. Uncontrolled intercurrent illness including but not limited to:

    • Symptomatic neurological illness
    • Active uncontrolled systemic infection considered opportunistic, life threatening or clinically significant at the time of treatment
    • Significant pulmonary disease or hypoxia
    • Psychiatric illness/social situations that would limit compliance with trial requirements
    • Human immunodeficiency virus (HIV)-positive patients
    • Known hepatitis B or C infection
    • Uncontrolled diabetes mellitus
  4. Serum potassium, magnesium, and calcium levels no more than 10% outside the Sites normal reference ranges
  5. Known serious cardiac illness including but not confined to:

    • Clinically unstable cardiac disease, including unstable atrial fibrillation, symptomatic bradycardia, unstable congestive heart failure, active myocardial ischemia, or indwelling temporary pacemaker
    • Ventricular tachycardia or a supraventricular tachycardia that requires treatment with a Class Ia anti-arrhythmic drug (e.g., quinidine, procainamide, disopyramide) or Class III anti-arrhythmic drug (e.g., sotalol, amiodarone, dofetilide). Use of other anti-arrhythmic drugs is permitted.
    • Use of medications that have been linked to the occurrence of torsades de pointes
    • Second- or third-degree atrioventricular (AV) block unless treated with a permanent pacemaker
    • Complete left bundle branch block (LBBB)
    • History of long QT Syndrome or a family member with this condition
    • QTc >470ms (average of triplicate ECG recordings); a consistent method of QTc calculation must be used for each patient's QTc measurements. QTcF (Fridericia's formula) is preferred
  6. The patient has a history of prior malignant tumour, unless the patient has been without evidence of disease for at least three years, or the tumour was a non-melanoma skin tumour or in situ cervix carcinoma
  7. Pregnant women or those who are lactating
  8. Pre-planned surgery or procedures that would interfere with the conduct of the trial
  9. Patients who have had surgery (does not include pleurodesis or pleurectomy) within 28 days of randomisation should not be included
  10. Previous treatment of mesothelioma with systemic chemotherapy
  11. Receipt of extensive radiation therapy, systemic chemotherapy, or other anti-neoplastic therapy within 4 weeks before enrolment is not allowed. However, drain site radiotherapy is allowed
  12. Significant weight loss (≥10% body weight) within the 4 weeks prior to Cycle 1 Day 1.
  13. Patients who have had a yellow fever vaccination in the previous 30 days.
  14. Other medications, severe acute/chronic medical or psychiatric condition, or laboratory abnormality that may increase the risk associated with study participation or study drug administration, or may interfere with the interpretation of study results, and in the judgment of the investigator would make the subject inappropriate for entry into this study.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01590160

United Kingdom
UCL Cancer Trials Centre
London, United Kingdom, W1T 4TJ
Sponsors and Collaborators
University College, London
Cancer Research UK
Study Chair: Professor D Fennell, MBBS University of Leicester & Leicester University Hospitals
  More Information

Responsible Party: University College, London Identifier: NCT01590160     History of Changes
Other Study ID Numbers: UCL/12/0158
CMS # 1995 ( Other Grant/Funding Number: Synta Pharmaceuticals )
A15183 ( Other Grant/Funding Number: Cancer Research UK Endorsement )
2012-001598-10 ( EudraCT Number )
TBC ( Registry Identifier: ISRCTN )
Study First Received: April 30, 2012
Last Updated: October 26, 2016

Additional relevant MeSH terms:
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms, Mesothelial
Antineoplastic Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Folic Acid Antagonists
Nucleic Acid Synthesis Inhibitors processed this record on April 21, 2017